Regulatory Submission & Approval Learning Path

The Regulatory Submission & Approval Learning Path is designed to equip professionals with the knowledge and skills required to navigate the full spectrum of regulatory submission activities — from clinical study report preparation and data integrity management through to regional regulatory frameworks and inspection readiness. Covering CSR management, project management for regulatory milestones, ALCOA+ documentation standards, FDA 21 CFR Part 11, EU GMP Annex 11, EU CTR 2021/1248, this programme provides a structured pathway to regulatory submission competence across major global markets.

Participants will develop a comprehensive understanding of the documentation, data integrity, electronic records, and regional regulatory requirements that underpin successful NDA, MAA, and BLA submissions — as well as the inspection readiness practices that protect approved submissions from post-approval regulatory risk.

How this differs from the Phase II & III Learning Path

The Regulatory Submission & Approval Learning Path focuses on the activities that follow clinical trial completion — CSR writing, data integrity assurance, electronic records compliance, regional regulatory adaptation, and inspection readiness. It is designed for professionals whose primary responsibility is transforming clinical data into compliant regulatory submissions.

In comparison, the Phase II & III Learning Path addresses operational trial delivery — protocol management, monitoring, site networks, and data collection. This submission and approval learning path is the natural next step for professionals who want to move from trial delivery into the regulatory affairs and dossier management activities that translate clinical evidence into product approval.